Patents Examined by Amelia A. Owens
  • Patent number: 7365216
    Abstract: The invention relates to a process for the manufacture of salts of citalopram in high purity. By the careful selection of solvents and the careful manipulation of the pH value, citalopram salts may be isolated in the absence of 5-chlorocitalopram, 5-bromocitalo-pram, desmethyl-citalopram and 5-carobxyamide citalopram.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: April 29, 2008
    Assignee: Matrix Laboratories Limited
    Inventors: Jyothi Basu Abbineni, Hari Babu Bodepudi, Satyanarayana Chava, Venkata Ramana Rao Chunchu
  • Patent number: 7358383
    Abstract: The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.
    Type: Grant
    Filed: January 26, 2004
    Date of Patent: April 15, 2008
    Assignees: University of South Florida, McGill University, The Hong Kong Polytechnic University
    Inventors: Q. Ping Dou, Tak-Hang Chan, David M. Smith
  • Patent number: 7329751
    Abstract: A process for the preparation of clopidogrel (1) by reaction of the N,N?-bis-4,5,6,7-tetrahydro-[3,2-c]-thienopyridyl methane (12) with (R)-2-chlorophenylacetic acid derivatives of formula (13) in which X and R have the meanings as indicated in the disclosure.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: February 12, 2008
    Assignee: Dipharma S.p.A.
    Inventors: Graziano Castaldi, Giuseppe Barreca, Alberto Bologna
  • Patent number: 7323578
    Abstract: Process for manufacturing an oxirane by reaction between an olefin and a peroxide compound in a reactor containing a liquid phase, in the presence of water, one or more organic solvents, a catalyst and one or more compounds for increasing the selectivity of the catalyst toward epoxidation reactions, in which: if the process is performed in batchwise mode, the liquid phase present in the reactor when the reaction starts, if the process is performed continuously, all of the liquid phases that are fed continuously into the reactor has/have a total organic solvent content of at least 0.1 g/kg and of not more than 675 g/kg.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: January 29, 2008
    Assignee: Solvay (Societe Anonyme)
    Inventors: Jean-Pierre Catinat, Michel Strebelle
  • Patent number: 7321039
    Abstract: The invention relates to a new industrially useable process for preparing tropenol, optionally in the form of the acid addition salts thereof.
    Type: Grant
    Filed: January 18, 2005
    Date of Patent: January 22, 2008
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rolf Banholzer, Gisela Bodenbach, Andreas Mathes, Helmut Meissner, Peter Specht
  • Patent number: 7317115
    Abstract: The object of the present invention is a novel mandelate salt of a substituted tetracyclic tetrahydrofuran derivative according to Formula (I) the N-oxide forms and the stereochemically isomeric forms thereof, wherein R1 and R2 each independently are hydrogen or C1-6alkyl and R3 and R4 each independently are hydrogen or halogen. In the foregoing definitions C1-6alkyl defines straight and branched saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, 1-methylpropyl, 1,1-dimethylethyl, pentyl or hexyl. The novel mandelate salt is not light-sensitive and is far more stable than the prior art salts at room temperature, enhanced temperature and at relative high humidities and in aqueous media.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: January 8, 2008
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Bart Petrus Anna Maria Jozef Medaer, Sigrid Carl Maria Stokbroekx, Yves Georges Ruysschaert, Joannes Josephus Maria Willems, Johan Erwin Edmond Weerts
  • Patent number: 7314943
    Abstract: The invention relates to pyran derivatives of formula I and processes and intermediates for their preparation and derivatisation, and the use thereof in liquid-crystalline media.
    Type: Grant
    Filed: May 25, 2004
    Date of Patent: January 1, 2008
    Assignee: Merck Patent GmbH
    Inventors: Eike Poetsch, Volker Meyer, Werner Binder, Michael Heckmeier, Georg Luessem, Stephan Guertler
  • Patent number: 7312231
    Abstract: A compound which is a carbamate of formula: wherein R1 represents R2 represents a benzyl, phenethyl, furan-2-ylmethyl, furan-3-ylmethyl, thiophen-2-ylmethyl or thiophen-3-ylmethyl group or a straight or branched alkyl group having 3 to 8 carbon atoms, an alkenyl group having 3 to 8 carbon atoms, or a cycloalkyl group of 3 to 6 carbon atoms; p is 1 or 2 and the substitution in the azoniabicyclic ring may be in the 2, 3 or 4 position including all possible configurations of the asymmetric carbons; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 31, 2003
    Date of Patent: December 25, 2007
    Assignee: Almirall Prodesfarma AG
    Inventors: Maria Antonia Buil Albero, Dolors Fernandez Forner, Maria Prat Quiñones
  • Patent number: 7312344
    Abstract: A compound of the general formula (I) or (II) wherein X is O, NR4 or S and R1-R8 are as defined in the specification
    Type: Grant
    Filed: March 8, 2002
    Date of Patent: December 25, 2007
    Assignee: Novogen Research Pty Limited
    Inventors: Andrew Heaton, Graham Edmund Kelly, Naresh Kumar
  • Patent number: 7312242
    Abstract: Compounds of the formula having anti-tumor activity, wherein R1 and R2 are as described herein
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: December 25, 2007
    Assignee: University of Kentucky
    Inventors: Peter A. Crooks, Craig T. Jordan, Xiaochen Wei
  • Patent number: 7304092
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions and methods for treating tumors, cancer and hyperproliferative diseases including psoriasis, genital warts and hyperproliferative cell growth diseases, including hyperproliferative keratinocyte diseases such as hyperkeratosis, ichthyosis, keratoderma or lichen planus.
    Type: Grant
    Filed: November 11, 2003
    Date of Patent: December 4, 2007
    Assignee: Yale University
    Inventors: David J. Austin, Viet-Ahn A. Nguyen, Doris Pupowicz, Albert Deisseroth, Tao Wang, Enrica Lerma
  • Patent number: 7297702
    Abstract: Competitive progesterone antagonists, including two novel steroids, viz., 11?,19-[4-(cyanophenyl)-o-phenylene]-17?-hydroxy-17?-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11?,19-[4-(3-pyridinyl)-o-phenylene]-17?-hydroxy-17?-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one, inhibit formation of endometrial glands at below their ovulation inhibiting dose and the abortive dose, and thus achieve oral contraception in females without adversely affecting the menstrual cycle and without risk of aborting a previous implanted fertilized egg or a fetus.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: November 20, 2007
    Assignee: Schering Aktiengesellschaft
    Inventors: Krzysitof Chwalisz, Walter Elger, Karin Schmidt-Gollwitzer, Eckhard Ottow
  • Patent number: 7291734
    Abstract: N-(4,5,6,7-tetrahydro-thiazolo-[5,4-c]pyridin-2-yl)-(C6-18)arylsulfonamides, wherein the nitrogen atom of the pyridine is substituted, and wherein the pyridine ring is optionally bridged, useful as a pharmaceutical related to steroid sulfatase
    Type: Grant
    Filed: November 13, 2003
    Date of Patent: November 6, 2007
    Assignee: Novartis AG
    Inventor: Erwin P Schreiner
  • Patent number: 7285671
    Abstract: The subject invention provides anticoagulant compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R3, n and Ar are as defined herein. The compounds of the subject invention can be used to treat at-risk populations thereby bringing relief of symptoms, improving the quality of life, preventing acute and long-term complications, reducing mortality and treating accompanying disorders. The invention further comprises pharmaceutical compositions comprising the compounds and salts of the invention, as well as methods of using the compounds, salts, and compositions of the invention.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: October 23, 2007
    Assignee: ARYx Therapeutics
    Inventors: Pascal Druzgala, Cyrus Becker
  • Patent number: 7279500
    Abstract: Cannabinoid agonists and antagonists are provided for use in the treatment of disorders such as acute and chronic pain, inflammation, loss of appetite, convulsions, multiple sclerosis, nausea and vomiting. The cannabinoid agonists and antagonists contain a sulfonamide moiety incorporated into the cannabinoid side chain, and the side chain itself may be saturated or unsaturated.
    Type: Grant
    Filed: June 24, 2003
    Date of Patent: October 9, 2007
    Assignee: Virginia Commonwealth University
    Inventors: Billy R. Martin, Raj K. Razdan, Roger G. Pertwee
  • Patent number: 7276533
    Abstract: This invention features the use of the spirolaxine of formula (I) for the treatment of those pathologies responding to the activation of the PPAR? receptor, such as the Type 2 insulin-resistant diabetes. This invention also features a pharmaceutical composition in which the spirolaxine of formula (I) acts as active principle in association with the all-trans retinoic acid of formula (II) for the treatment of those pathologies responding to the activation of the PPAR? receptor, such as the acute malignant haemopathies.
    Type: Grant
    Filed: July 13, 2004
    Date of Patent: October 2, 2007
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Claudio Pisano, Teresa Riccioni
  • Patent number: 7273886
    Abstract: Compounds of Formula I are useful for inhibiting serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein and have improved pharmacokinetic properties. These compounds may be used in methods of preventing and/or treating clotting disorders.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: September 25, 2007
    Assignee: Genentech, Inc.
    Inventors: Alan G. Olivero, Daniel P. Sutherlin
  • Patent number: 7273936
    Abstract: Novel oxazole and thiazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-? signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: September 25, 2007
    Assignee: Pfizer Inc.
    Inventors: Michael J. Munchhof, Laura C. Blumberg
  • Patent number: 7265116
    Abstract: Provided herein are compounds of the formula (I): wherein R1-R8 are as described herein, R4 being phthalazinyl, pyrazinyl, pyridazinyl, or quinoxalinyl. Such compounds are particularly useful in the treatment of a disorder which is created by or is dependent upon decreased availability of serotonin, norepinephrine, or dopamine.
    Type: Grant
    Filed: August 13, 2004
    Date of Patent: September 4, 2007
    Assignee: ARM Technology, Inc.
    Inventors: James P. Beck, Matt A. Curry, Mark A. Smith
  • Patent number: 7259267
    Abstract: The invention relates to difluorobenzo-1,3-dioxoles, to a process for their preparation, and to their use for preparing medicaments and crop protection agents.
    Type: Grant
    Filed: May 11, 2005
    Date of Patent: August 21, 2007
    Assignee: LANXESS Deutschland GmbH
    Inventors: Axel Pleschke, Albrecht Marhold